OncoSec Medical (ONCS) Stock Analysis

What OncoSec Medical does

OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to creating, advancing, and bringing to market DNA-based therapeutics designed for direct injection into tumors. These therapies aim to activate and amplify the body's anti-cancer immune responses. Its primary therapeutic candidate, ImmunoPulse IL-12 (also known as TAVO), employs an electroporation device to administer DNA encoding interleukin-12 directly into tumors, thereby counteracting the tumor's immunosuppressive environment. OncoSec's clinical pipeline includes several programs for ImmunoPulse IL-12. In combination with KEYTRUDA, it is being investigated for advanced melanoma (under a collaboration and supply agreement, KEYNOTE-695) and for metastatic triple-negative breast cancer (currently in Phase II trials, KEYNOTE-890). Earlier Phase II trials of ImmunoPulse IL-12 combined with KEYTRUDA for advanced or metastatic melanoma, and ImmunoPulse IL-12 as a monotherapy for metastatic melanoma, have both been completed. The company has also completed a Phase II monotherapy biomarker study for advanced or metastatic TNBC. Furthermore, OncoSec is developing its technology for broader application in treating various visceral lesions, including those in the liver, lungs, bladder, and pancreas. Strategic alliances are central to OncoSec's strategy, including clinical trial collaborations with Merck & Co., Inc. for the KEYNOTE-695 and KEYNOTE-890 studies. Research collaborations include Duke University's Center for Applied Therapeutics, exploring TAVO alongside a HER2-plasmid vaccine, and Roswell Park Comprehensive Cancer Center, focusing on intravital microscopy and enhanced IL-12 DNA-plasmids. The company also collaborates with Providence Cancer Institute. Originally incorporated in 2008 as NetVentory Solutions Inc., the company rebranded to OncoSec Medical Incorporated in March 2011 and operates from its headquarters in Pennington, New Jersey.

Key metrics

ETFs linked to ONCS

Broad-market and Healthcare sector ETFs an investor holding OncoSec Medical is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ONCS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for OncoSec Medical?

OncoSec Medical trades under the ticker ONCS on NASDAQ.

Which exchange is ONCS listed on?

ONCS is listed on NASDAQ.

What sector does OncoSec Medical operate in?

OncoSec Medical is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ONCS in a portfolio?

PortView shows ONCS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.